General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Icosavax in US$100 Million Series B Financing

April 7, 2021
A corporate deal team advised on the financing that will support the development of vaccines against life-threatening respiratory viruses.

Icosavax, Inc. has announced the close of a US$100 million Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company). Icosavax’s existing investors also participated, including Qiming Venture Partners USA, Adams Street Partners, Sanofi Ventures, and ND Capital. A previously announced funding from Open Philanthropy was included in this round. The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus and human metapneumovirus vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.

Latham & Watkins LLP represented Icosavax, Inc. in the transaction with a corporate deal team led by San Diego partner Cheston Larson and San Diego counsel Chris Geissinger, with New York associate Teddy Ellison and San Diego associate Michael Grega. Advice was also provided on benefits and compensation matters by San Diego partner Holly Bauer, with Orange County associate Sara Schlau.